ALXO
ALX Oncology Holdings Inc. NASDAQ Listed Jul 17, 2020$1.86
Mkt Cap $101.1M
52w Low $0.40
64.8% of range
52w High $2.66
50d MA $1.94
200d MA $1.53
P/E (TTM)
-0.9x
EV/EBITDA
-0.5x
P/B
3.5x
Debt/Equity
0.2x
ROE
-391.4%
P/FCF
-0.7x
RSI (14)
—
ATR (14)
—
Beta
0.50
50d MA
$1.94
200d MA
$1.53
Avg Volume
986.6K
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
323 Allerton Avenue · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | AMC | -0.38 | -0.42 | -10.5% | 2.11 | -4.3% | +0.5% | -1.9% | +3.8% | +0.9% | +4.7% | — |
| Nov 7, 2025 | AMC | -0.37 | -0.41 | -10.8% | 1.38 | -8.0% | -8.0% | -5.1% | -7.2% | -11.6% | +0.0% | — |
| Aug 12, 2025 | AMC | -0.46 | -0.49 | -6.5% | 0.62 | +0.8% | +7.4% | +6.5% | +4.7% | +57.8% | +44.6% | — |
| May 8, 2025 | AMC | -0.47 | -0.58 | -23.4% | 0.46 | +3.3% | -8.2% | -5.4% | +4.5% | -0.2% | -5.3% | — |
| Mar 6, 2025 | AMC | -0.72 | -0.55 | +23.6% | 1.31 | -4.6% | -19.1% | -31.8% | -25.7% | -26.8% | -36.5% | — |
| Nov 7, 2024 | AMC | -0.78 | -0.58 | +25.6% | 1.51 | +2.6% | -4.0% | -2.0% | -11.3% | -11.3% | -11.9% | — |
| Aug 8, 2024 | AMC | -0.77 | -0.76 | +1.3% | 2.63 | +4.2% | -0.8% | -4.2% | +0.4% | -1.9% | +0.8% | — |
| May 9, 2024 | AMC | -0.87 | -0.71 | +18.4% | 16.95 | +3.2% | -4.4% | -7.9% | -10.5% | -11.4% | -13.5% | — |
| Mar 7, 2024 | AMC | -0.84 | -0.93 | -10.7% | 16.24 | -13.1% | -6.3% | -17.1% | -23.8% | -28.6% | -31.3% | — |
| Nov 13, 2023 | AMC | -0.86 | -1.24 | -44.2% | 8.43 | -8.9% | +4.7% | +4.0% | +5.9% | +12.7% | +16.3% | — |
| Aug 10, 2023 | AMC | -0.85 | -0.84 | +1.2% | 5.04 | -2.0% | +0.4% | -2.8% | -3.6% | -9.7% | -9.5% | — |
| May 11, 2023 | AMC | -0.84 | -0.58 | +31.0% | 6.27 | +3.5% | +4.1% | +3.0% | -3.7% | +0.6% | -4.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.13 | $2.18 | +2.3% | -4.2% | +0.9% | -5.2% | -7.0% | -2.3% |
| Feb 5 | Piper Sandler | Maintains | Overweight → Overweight | — | $2.01 | $2.10 | +4.5% | +2.5% | +2.0% | +16.4% | +26.9% | +23.4% |
| May 21 | UBS | Maintains | Buy → Buy | — | $0.43 | $0.43 | +0.0% | -4.6% | +11.7% | +8.1% | +4.5% | +4.5% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.46 | $0.48 | +3.3% | -8.2% | -5.4% | +4.5% | -0.2% | -5.3% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.31 | $1.25 | -4.6% | -19.1% | -31.8% | -25.7% | -26.8% | -36.5% |
| Mar 7 | Stifel | Maintains | Hold → Hold | — | $1.31 | $1.25 | -4.6% | -19.1% | -31.8% | -25.7% | -26.8% | -36.5% |
| Mar 6 | Jefferies | Upgrade | Hold → Buy | — | $1.04 | $1.07 | +2.9% | +26.0% | +1.9% | -14.1% | -6.4% | -7.8% |
| Mar 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.04 | $1.07 | +2.9% | +26.0% | +1.9% | -14.1% | -6.4% | -7.8% |
| Jan 27 | UBS | Maintains | Buy → Buy | — | $1.52 | $1.45 | -4.6% | +2.6% | +0.7% | -3.9% | -13.8% | -3.9% |
| Jan 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.63 | $1.55 | -4.9% | -6.7% | -4.3% | -6.1% | -10.4% | -19.6% |
| Jan 24 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.63 | $1.55 | -4.9% | -6.7% | -4.3% | -6.1% | -10.4% | -19.6% |
| Dec 19 | Jefferies | Downgrade | Buy → Hold | — | $1.84 | $1.78 | -3.3% | -19.6% | -12.0% | +1.6% | -0.5% | -8.2% |
| Dec 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.79 | $1.82 | +1.7% | +2.8% | -17.3% | -9.5% | +4.5% | +2.2% |
| Dec 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.79 | $1.82 | +1.7% | +2.8% | -17.3% | -9.5% | +4.5% | +2.2% |
| Aug 16 | UBS | Maintains | Buy → Buy | — | $2.65 | $2.62 | -1.1% | -4.2% | -3.0% | -5.3% | -5.7% | -12.1% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.52 | $2.46 | -2.4% | +4.8% | +2.4% | +5.2% | +0.8% | +2.0% |
| Aug 9 | Stifel | Maintains | Hold → Hold | — | $2.63 | $2.74 | +4.2% | -0.8% | -4.2% | +0.4% | -1.9% | +0.8% |
| Aug 1 | Stifel | Maintains | Hold → Hold | — | $4.80 | $3.20 | -33.3% | -41.7% | -40.4% | -43.1% | -42.7% | -46.5% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.80 | $3.20 | -33.3% | -41.7% | -40.4% | -43.1% | -42.7% | -46.5% |
| Jun 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.01 | $8.86 | -1.7% | -3.8% | -5.0% | -5.3% | -6.3% | -10.7% |
| Apr 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.34 | $12.02 | -2.6% | -2.4% | +8.4% | +5.6% | +4.5% | +17.4% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.21 | $15.58 | +2.4% | -11.5% | -18.7% | -23.7% | -26.7% | -25.7% |
| Mar 8 | Stifel | Downgrade | Buy → Hold | — | $16.24 | $14.12 | -13.1% | -6.3% | -17.1% | -23.8% | -28.6% | -31.3% |
| Mar 8 | Piper Sandler | Maintains | Overweight → Overweight | — | $16.24 | $14.12 | -13.1% | -6.3% | -17.1% | -23.8% | -28.6% | -31.3% |
| Dec 8 | Jefferies | Upgrade | Hold → Buy | — | $9.25 | $10.22 | +10.5% | +32.5% | +35.1% | +38.5% | +43.8% | +42.6% |
| Nov 14 | Stifel | Maintains | Buy → Buy | — | $8.43 | $7.68 | -8.9% | +4.7% | +4.0% | +5.9% | +12.7% | +16.3% |
| Oct 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $9.52 | $9.43 | -0.9% | -4.5% | -0.7% | -4.1% | -2.6% | -10.7% |
| Oct 4 | UBS | Maintains | Buy → Buy | — | $7.51 | $7.12 | -5.2% | -15.0% | -12.7% | +11.2% | +9.1% | +26.8% |
| Oct 4 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $7.51 | $7.12 | -5.2% | -15.0% | -12.7% | +11.2% | +9.1% | +26.8% |
| Oct 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.81 | $8.09 | +68.2% | +56.1% | +32.6% | +36.3% | +73.6% | +70.3% |
| Sep 12 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.96 | $4.89 | -1.4% | +1.8% | +3.8% | +1.0% | +4.4% | +4.0% |
| Aug 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.06 | $5.02 | -0.8% | -3.2% | -4.0% | -10.1% | -9.9% | -6.9% |
| Aug 11 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.04 | $4.94 | -2.0% | +0.4% | -2.8% | -3.6% | -9.7% | -9.5% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.04 | $4.94 | -2.0% | +0.4% | -2.8% | -3.6% | -9.7% | -9.5% |
| Aug 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $5.04 | $4.94 | -2.0% | +0.4% | -2.8% | -3.6% | -9.7% | -9.5% |
| Jul 24 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $6.73 | $6.45 | -4.2% | -8.5% | -12.9% | -12.9% | -15.3% | -11.7% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.27 | $6.49 | +3.5% | +4.1% | +3.0% | -3.7% | +0.6% | -4.1% |
| Mar 15 | UBS | Maintains | Buy → Buy | — | $5.25 | $5.21 | -0.8% | -1.1% | -4.8% | -9.1% | -12.2% | -8.4% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.87 | $5.79 | -1.4% | -8.2% | -4.1% | -10.6% | -11.6% | -14.8% |
| Mar 10 | Credit Suisse | Maintains | Outperform → Outperform | — | $5.87 | $5.79 | -1.4% | -8.2% | -4.1% | -10.6% | -11.6% | -14.8% |
| Nov 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.50 | $12.63 | +1.0% | -0.6% | +0.9% | +2.3% | -1.0% | -7.2% |
| Aug 9 | Credit Suisse | Maintains | Outperform → Outperform | — | $11.76 | $11.39 | -3.1% | +0.1% | +8.8% | +10.4% | +23.5% | +28.7% |
| Jun 6 | Stifel | Maintains | Buy → Buy | — | $7.60 | $7.72 | +1.6% | -5.9% | +2.0% | +5.0% | +2.4% | -10.7% |
| May 19 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.64 | $8.66 | +0.2% | +1.4% | +1.3% | -2.1% | -10.3% | -8.6% |
| Mar 1 | Stifel | Maintains | Buy → Buy | — | $18.12 | $17.52 | -3.3% | +0.1% | +4.1% | -3.9% | -8.2% | -5.4% |
| Dec 22 | Jefferies | Downgrade | Buy → Hold | — | $22.91 | $21.62 | -5.6% | -2.7% | +1.5% | -2.4% | -2.8% | -4.3% |
| Sep 30 | Stifel | Maintains | Buy → Buy | — | $73.36 | $75.03 | +2.3% | +0.7% | +1.4% | -3.1% | +0.7% | -6.5% |
| Apr 6 | UBS | Maintains | Buy → Buy | — | $75.23 | $76.75 | +2.0% | -0.8% | -8.0% | -4.1% | -15.2% | -23.0% |
| Feb 11 | Credit Suisse | Maintains | Outperform → Outperform | — | $80.42 | $83.34 | +3.6% | +0.6% | +1.7% | +1.4% | +5.8% | +6.9% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $82.18 | $85.75 | +4.3% | -2.1% | -1.5% | -0.5% | -0.8% | +3.5% |
No insider trades available.
8-K · 2.02
!! High
ALX Oncology Holdings Inc. -- 8-K 2.02: Earnings Results
ALX Oncology reported quarterly earnings results, with detailed financial performance metrics now available in their press release filing.
May 8
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Leadership transitions create uncertainty around strategic direction and operational continuity, potentially triggering stock volatility until investors assess the successor's qualifications and vision.
Apr 13
8-K
ALX Oncology Holdings Inc. -- 8-K Filing
ALX Oncology reported positive Phase 1b/2 biomarker data supporting its evorpacept and zanidatamab combination for HER2-positive breast cancer, advancing clinical development of its immunotherapy pipeline.
Feb 27
Data updated apr 24, 2026 5:37pm
· Source: massive.com